Henrik Falhammar1, Jonatan D Lindh2, Jan Calissendorff3, Shermineh Farmand4, Jakob Skov5, David Nathanson4, Buster Mannheimer4. 1. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden. Electronic address: henrik.falhammar@ki.se. 2. Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden. 3. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden. 4. Department of Clinical Science and Education at Södersjukhuset, Karolinska Institutet, Stockholm, Sweden. 5. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Abstract
PURPOSE: Hyponatremia induced by antiepileptic drugs is common, but detailed evidence is lacking. This can be problematic for the treating neurologist confronted with a patient with severe hyponatremia in need of an alternative drug. The objective of this study was to examine the association between individual antiepileptic drugs and hospitalization due to hyponatremia. METHODS: This was a register-based case-control study of patients in the general Swedish population. We included 14,359 individuals with a principal diagnosis of hyponatremia and 57,383 matched controls. The association between newly initiated (≤90 days) and ongoing antiepileptic treatment was investigated using multivariable logistic regression adjusting for concomitant drugs, medical conditions, previous hospitalizations and sociaoeconomic factors. RESULTS: For newly initiated antiepileptic drugs, adjusted ORs (95% CI) for hospitalization due to hyponatremia, compared to controls, were: carbamazepine 9.63 (6.18-15.33); phenytoin 4.83 (1.14-25.76); valproate 4.96 (2.44-10.66); lamotrigine 1.67 (0.70-4.08); levetiracetam 9.76 (4.02-27.59) and gabapentin 1.61 (1.08-2.38). Newly initiated oxcarbazepine treatment was only found in the hyponatremia group and not in controls. Adjusted ORs (CI) for individuals with ongoing treatment ranged from 7.97 (3.70-18.50) for oxcarbazepine to 0.83 (0.64-1.06) for gabapentin. CONCLUSION: There was a strong association between newly initiated treatment with carbamazepine, oxcarbazepine and levetiracetam, and hospitalization due to hyponatremia. The corresponding association for phenytoin and valproate was moderate. The risk for hyponatremia was lower during ongoing treatment. Lamotrigine and gabapentin had the lowest risk both during initiation and ongoing treatment and may be advantageous in patients at risk of developing hyponatremia.
PURPOSE:Hyponatremia induced by antiepileptic drugs is common, but detailed evidence is lacking. This can be problematic for the treating neurologist confronted with a patient with severe hyponatremia in need of an alternative drug. The objective of this study was to examine the association between individual antiepileptic drugs and hospitalization due to hyponatremia. METHODS: This was a register-based case-control study of patients in the general Swedish population. We included 14,359 individuals with a principal diagnosis of hyponatremia and 57,383 matched controls. The association between newly initiated (≤90 days) and ongoing antiepileptic treatment was investigated using multivariable logistic regression adjusting for concomitant drugs, medical conditions, previous hospitalizations and sociaoeconomic factors. RESULTS: For newly initiated antiepileptic drugs, adjusted ORs (95% CI) for hospitalization due to hyponatremia, compared to controls, were: carbamazepine 9.63 (6.18-15.33); phenytoin 4.83 (1.14-25.76); valproate 4.96 (2.44-10.66); lamotrigine 1.67 (0.70-4.08); levetiracetam 9.76 (4.02-27.59) and gabapentin 1.61 (1.08-2.38). Newly initiated oxcarbazepine treatment was only found in the hyponatremia group and not in controls. Adjusted ORs (CI) for individuals with ongoing treatment ranged from 7.97 (3.70-18.50) for oxcarbazepine to 0.83 (0.64-1.06) for gabapentin. CONCLUSION: There was a strong association between newly initiated treatment with carbamazepine, oxcarbazepine and levetiracetam, and hospitalization due to hyponatremia. The corresponding association for phenytoin and valproate was moderate. The risk for hyponatremia was lower during ongoing treatment. Lamotrigine and gabapentin had the lowest risk both during initiation and ongoing treatment and may be advantageous in patients at risk of developing hyponatremia.
Authors: Robert T Wechsler; Rodney A Radtke; Michael Smith; David G Vossler; Laura Strom; Eugen Trinka; Hailong Cheng; Todd Grinnell; David Blum; Mariana Vieira; Joana Moreira; Francisco Rocha Journal: Epilepsia Date: 2019-07-01 Impact factor: 5.864
Authors: Jonatan D Lindh; David Nathanson; Buster Mannheimer; Jakob Skov; Henrik Falhammar; Jan Calissendorff Journal: Endocrine Date: 2019-09-02 Impact factor: 3.633
Authors: Henrik Falhammar; Jakob Skov; Jan Calissendorff; Jonatan D Lindh; Buster Mannheimer Journal: J Psychopharmacol Date: 2020-07-20 Impact factor: 4.153
Authors: Henrik Falhammar; Jakob Skov; Jan Calissendorff; David Nathanson; Jonatan D Lindh; Buster Mannheimer Journal: J Clin Endocrinol Metab Date: 2020-10-01 Impact factor: 5.958
Authors: Buster Mannheimer; Henrik Falhammar; Jan Calissendorff; Jakob Skov; Jonatan D Lindh Journal: J Psychopharmacol Date: 2021-04-16 Impact factor: 4.153
Authors: Johanna Seifert; Martin Letmaier; Timo Greiner; Michael Schneider; Maximilian Deest; Christian K Eberlein; Stefan Bleich; Renate Grohmann; Sermin Toto Journal: J Neural Transm (Vienna) Date: 2021-07-01 Impact factor: 3.575